Fig. 6

Slc11a1 Knockdown Reduces ROS, Ferrous Ion Contents and NETs Production in Human Neutrophils In Vitro. A Human neutrophils were treated with the TCb chemotherapeutic agent or transfected with Slc11a1 small interfering RNA (siRNA). Slc11a1 mRNA levels were measured by q-PCR. TCb treatment significantly increased Slc11a1 mRNA expression, which was reversed upon knockdown of Slc11a1, B, C western blot analysis showed that TCb treatment significantly elevated NRAMP1 protein levels in human neutrophils, which was reversed by Slc11a1 knockdown, D–F intracellular ferrous ion levels, measured using the FerroOrange probe in human neutrophils, showed a significant increase in TCb-treated groups, attenuated by Slc11a1 knockdown, G, H ROS levels in TCb-treated human neutrophils demonstrated a marked elevation compared to controls, which was reversed by Slc11a1 knockdown, I quantification of dsDNA in cell culture supernatants showed a significant increase in TCb-treated human neutrophils, which was significantly reversed by Slc11a1 knockdown, J MPO and histone H3 concentrations in the culture supernatants of TCb-treated human neutrophils were elevated but reversed by Slc11a1 knockdown. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001